Costco Wholesale (COST) Q4, FY15 Sales Lighter than Expected

Costco Wholesale (NASDAQ: COST) reported net sales of $8.7 billion for the month of August, the four weeks ended August 30, 2015, a decrease of one percent from $8.8 billion during the similar period last year.

For the 16-week fourth quarter, the Company reported net sales of $35.0 billion, an increase of one percent from $34.8 billion in the fourth quarter last year, which ended August 31, 2014.

For the 52-week fiscal year ended August 30, 2015, the Company reported net sales of $113.7 billion, an increase of three percent from the $110.2 billion reported last year.

*** Consensus estimates called for Q4 sales of $36.5 billion and FY15 revenue of $117.1 billion.

Comparable sales for the four, sixteen, and fifty-two week periods were as follows:

                               4 Weeks  16 Weeks 52 Weeks

                               -------- -------- --------



                  U.S.            1%       2%       3%

                  International -11%      -9%      -4%



                  Total Company  -2%      -1%       1%

                               ======== ======== ========

Comparable sales for these periods, excluding the negative impacts from gasoline price deflation and foreign exchange, were as follows:

                               4 Weeks  16 Weeks 52 Weeks

                               -------- -------- --------



                  U.S.            5%       6%       6%

                  International   7%       7%       7%



                  Total Company   5%       6%       7%

                               ======== ======== ========

Additional discussion of these results is available in a pre-recorded telephone message. The recording can be accessed by dialing 1-855-859-2056 (conference ID 94066124). This message will be available today through 5:00 p.m. (PT) on Friday, September 4, 2015.

You May Also Be Interested In

• Trilogy Metals closes $35.6M investment from U.S. Department of War
• Corning (GLW) files for up to $2B offering of common shares
• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial